E. Robert Wassman, MD is Co-Director of Predictive Laboratories, a novel reproductive genetics lab, and also Director of Progenitor MDX. Both laboratories are currently focused on COVID-19 diagnostics. He also currently serves on the Board of Directors of the TESS Foundation, a non-profit focused on SLC13A5, and is medical advisor to TREND Community, which is focused on social listening in rare and emerging diseases. For over 40-years, Dr. Wassman has pioneered the introduction of genetic testing and personalized medicine. His focus has been on the translation and delivery of cutting-edge diagnostic technology to clinical service in the areas of reproductive medicine, rare cell/non-invasive diagnostics, and Next Generation DNA sequencing spanning clinical disciplines of reproductive genetics, cancer and companion diagnostics, and neurodevelopmental disabilities including autism. He has served as Chief Medical Officer for multiple companies in this space including Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health, Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, and Alfigen. He has co-founded several successful ventures, and served as a consultant on technical, clinical, operational, regulatory and reimbursement matters to a wide variety of entities. He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics.